Skip to content
10-Q

Quarterly Report

Lyell Immunopharma, Inc. LYEL

0001628280-25-051619

← back to feed
Filed
Nov 12, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Nov 10, 2025 21.22M sh
Shares Diluted Q3 2025 · Sep 30, 2025 18.27M sh
Shares Diluted Q3 2025 · Sep 30, 2025 15.95M sh
Shares Diluted restated Q3 2025 · Sep 30, 2024 12.82M sh
Shares Diluted restated Q3 2025 · Sep 30, 2024 12.77M sh
Capex Q3 2025 · Sep 30, 2025 $476K
Capex Q3 2025 · Sep 30, 2024 $420K
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$117.77M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$115.15M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $123.58M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $105.6M
Cash And Equivalents Q3 2025 · Sep 30, 2024 $100.3M
Stockholders Equity Q3 2025 · Sep 30, 2025 $329.12M
Stockholders Equity Q3 2025 · Jun 30, 2025 $298.92M
Stockholders Equity Q3 2025 · Dec 31, 2024 $382.82M
Stockholders Equity Q3 2025 · Sep 30, 2024 $530.7M
Stockholders Equity Q3 2025 · Jun 30, 2024 $566.5M
Stockholders Equity Q3 2025 · Dec 31, 2023 $654.95M
Current Liabilities Q3 2025 · Sep 30, 2025 $31.88M
Current Liabilities Q3 2025 · Dec 31, 2024 $53.79M
Total Liabilities Q3 2025 · Sep 30, 2025 $78.84M
Total Liabilities Q3 2025 · Dec 31, 2024 $108.04M
Current Assets Q3 2025 · Sep 30, 2025 $328.2M
Current Assets Q3 2025 · Dec 31, 2024 $379.59M
Total Assets Q3 2025 · Sep 30, 2025 $407.97M
Total Assets Q3 2025 · Dec 31, 2024 $490.86M
Eps Diluted Q3 2025 · Sep 30, 2025 −$2.13
Eps Diluted Q3 2025 · Sep 30, 2025 −$8.38
Eps Diluted restated Q3 2025 · Sep 30, 2024 −$3.48
Eps Diluted restated Q3 2025 · Sep 30, 2024 −$11.83
Eps Basic Q3 2025 · Sep 30, 2025 −$2.13
Eps Basic Q3 2025 · Sep 30, 2025 −$8.38
Eps Basic restated Q3 2025 · Sep 30, 2024 −$3.48
Eps Basic restated Q3 2025 · Sep 30, 2024 −$11.83
Sga Expense Q3 2025 · Sep 30, 2025 $10.69M
Sga Expense Q3 2025 · Sep 30, 2025 $34.52M
Sga Expense Q3 2025 · Sep 30, 2024 $11.77M
Sga Expense Q3 2025 · Sep 30, 2024 $37.52M
Rd Expense Q3 2025 · Sep 30, 2025 $28.17M
Rd Expense Q3 2025 · Sep 30, 2025 $106.48M
Rd Expense Q3 2025 · Sep 30, 2024 $39.5M
Rd Expense Q3 2025 · Sep 30, 2024 $122.94M
Net Income Q3 2025 · Sep 30, 2025 −$38.85M
Net Income Q3 2025 · Sep 30, 2025 −$133.73M
Net Income Q3 2025 · Sep 30, 2024 −$44.58M
Net Income Q3 2025 · Sep 30, 2024 −$151.06M
Operating Income Q3 2025 · Sep 30, 2025 −$37.25M
Operating Income Q3 2025 · Sep 30, 2025 −$141.76M
Operating Income Q3 2025 · Sep 30, 2024 −$50.51M
Operating Income Q3 2025 · Sep 30, 2024 −$157.61M
Revenue Q3 2025 · Sep 30, 2025 $15K
Revenue Q3 2025 · Sep 30, 2025 $30K
Revenue Q3 2025 · Sep 30, 2024 $34K
Revenue Q3 2025 · Sep 30, 2024 $50K